EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma

Giovanni Montesano, David F Garway-Heath, Alessandro Rabiolo, Carlos Gustavo De Moraes, Giovanni Ometto, David P Crabb

Translational Vision Science & Technology · 31.10.2023 · 12 (10) · 20

DOI: 10.1167/tvst.12.10.20 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Vision Science & Technology, erschienen am 31.10.2023. Verfasst von Giovanni Montesano und 5 weiteren Autor:innen. Beteiligte Einrichtung: City, University of London, Optometry and Visual Sciences, London, UK. Hauptthemen laut MEDLINE: Glaucoma, Neuroprotection. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The purpose of this study was to evaluate the power of trend-based visual field (VF) progression end points against long-term development of event-based end points accepted by the US Food and Drug Administration (FDA).

Methods

One eye from 3352 patients with ≥10 24-2 VFs (median = 11 years) follow-up were analyzed. Two FDA-compatible criteria were applied to these series to label "true-progressed" eyes: ≥5 locations changing from baseline by more than 7 dB (FDA-7) or by more than the expected test-retest variability (GPA-like) in 2 consecutive tests. Observed rates of progression (RoP) were used to simulate trial-like series (2 years) randomly assigned (1000 times) to a "placebo" or a "treatment" arm. We simulated neuroprotective "treatment" effects by changing the proportion of "true progressed" eyes in the two arms. Two trend-based methods for mean deviation (MD) were assessed: (1) linear mixed model (LMM), testing average difference in RoP between the two arms, and (2) time-to-progression (TTP), calculated by linear regression as time needed for MD to decline by predefined cutoffs from baseline. Power curves with 95% confidence intervals were calculated for trend and event-based methods on the simulated series.

Results

The FDA-7 and GPA-like progression was achieved by 45% and 55% of the eyes in the clinical database. LMM and TTP had similar power, significantly superior to the event-based methods, none of which reached 80% power. All methods had a 5% false-positive rate.

Conclusions

The trend-based methods can efficiently detect treatment effects defined by long-term FDA-compatible progression. Translational Relevance: The assessment of the power of trend-based methods to detect clinically relevant progression end points.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlaucomaNeuroprotectionHumansEyeUnited StatesVisual FieldsRandomized Controlled Trials as Topic

Autor:innen und Institutionen

  • City, University of London, Optometry and Visual Sciences, London, UK.
  • NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.
  • Department of Health Sciences, Università del Piemonte Orientale "A. Avogadro," Novara, Italy.
  • Eye Clinic, University Hospital Maggiore della Carità, Novara, Italy.
  • Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY, USA.

Zitieren

APA

Montesano, G., Garway-Heath, D. F., Rabiolo, A., De Moraes, C. G., Ometto, G., & Crabb, D. P. (2023). Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma. Translational Vision Science & Technology, 12(10), 20. https://doi.org/10.1167/tvst.12.10.20

Vancouver

Montesano G, Garway-Heath DF, Rabiolo A, De Moraes CG, Ometto G, Crabb DP. Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma. Translational Vision Science & Technology. 2023;12(10):20. doi:10.1167/tvst.12.10.20

BibTeX
@article{Montesano2023,
  author = {Montesano, Giovanni and Garway-Heath, David F and Rabiolo, Alessandro and De Moraes, Carlos Gustavo and Ometto, Giovanni and Crabb, David P},
  title = {Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma},
  journal = {Translational Vision Science & Technology},
  year = {2023},
  volume = {12},
  number = {10},
  pages = {20},
  doi = {10.1167/tvst.12.10.20}
}
Kostenlos starten →